Practical Insights for Treating Metastatic Colorectal Cancer: Bridging Research to Real-World Practice : Episode 2
Opinion
Video
Real-World Impact of SUNLIGHT Outcomes in mCRC
Medical experts discuss key takeaways from the SUNLIGHT trial, which compared FTD/TPI monotherapy to FTD/TPI plus bevacizumab for advanced metastatic colorectal cancer, including overall survival, safety, and benefits regardless of prior bevacizumab therapy, and how this data has influenced the use of FTD/TPI in the third-line setting compared with real-world outcomes.
- The recent SUNLIGHT trial compared FTD/TPI monotherapy to FTD/TPI in combination with bevacizumab for advanced metastatic colorectal cancer. Describe the key takeaways from this trial.
- Include in your discussion overall survival, safety profile, as well as benefit seen regardless of prior bevacizumab therapy.
- How has the SUNLIGHT data impacted your overall use of FTD/TPI in the third-line setting?
- How do the outcomes in SUNLIGHT compare with what you’ve seen as real-word outcomes?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
